Steven H. Swerdlow

TL;DR: The revision clarifies the diagnosis and management of lesions at the very early stages of lymphomagenesis, refines the diagnostic criteria for some entities, details the expanding genetic/molecular landscape of numerous lymphoid neoplasms and their clinical correlates, and refers to investigations leading to more targeted therapeutic strategies.

TL;DR: The characteristic features of these new and modified entities as well as the results of recent molecular studies with diagnostic, prognostic, and/or therapeutic significance for the different types of primary cutaneous lymphomas are reviewed.

TL;DR: Three of the most commonly mutated genes in FL were significantly less commonly mutated in PCFCL than in FL and TNFAIP was more commonly mutated, highlighting a distinctive mutational profile further supporting its recognition as a distinct entity.

TL;DR: The 2 subtypes of PCMZL create different diagnostic challenges and require the use of a multiparameter approach and emerging data suggest that the heavy chain class-switched cases may be more like a clonal chronic lymphoproliferative disorder.

TL;DR: How varied the practice of HP is and can provide guidance to HP PDs, those responsible for assessing HP programs, and the American Board of Pathology are highlighted.